Boston and Aspect make Alzheimer's/depression deal
This article was originally published in Clinica
Executive Summary
Boston Scientific has given Aspect Medical Systems $25m in a strategic alliance to develop new brain monitoring technology to help diagnose and treat depression, Alzheimer's disease (AD) and other neurological conditions.